Ralinepag
- Generic Name
- Ralinepag
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26ClNO5
- CAS Number
- 1187856-49-0
- Unique Ingredient Identifier
- CQY12ZJN6E
- Background
Ralinepag has been used in trials studying the treatment of Pulmonary Arterial Hypertension.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Ralinepag in Healthy Chinese Adult Subjects
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Everstar Medicines (Shanghai) Limited
- Target Recruit Count
- 15
- Registration Number
- NCT04613999
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT04084678
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇧🇷Centro de Hipertensão Pulmonar, Porto Alegre, Brazil
🇦🇹Ordensklinikum Linz GmbH, Elisabethinen, Linz, Austria
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 1000
- Registration Number
- NCT03683186
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center-Norton Thoracic Institute, Phoenix, Arizona, United States
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 1000
- Registration Number
- NCT03626688
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 45
- Registration Number
- NCT02279745
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇦🇺St Vincent's Hospital, Fitzroy, Victoria, Australia
🇧🇬Multiprofile Hospital for Active Treatment "National Heart Hospital" EAD, Clinic of Cardiology, Sofia, Bulgaria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.